特许权使用费收入表现 - 公司2022年第三季度特许权使用费收入为41.43万美元，同比增长18.6%[83][84] - 特许权使用费收入增长47.3%至122万美元，较上年同期82.8万美元增加39.2万美元[90][91] 研发费用变化 - 研发费用同比下降48.9%至39.88万美元，主要因XCART平台投入减少[83][85][86] - 研发费用激增84.9%至357.8万美元，主要因130万美元IPR&D支出（DNase肿瘤平台授权）[90][92] - 外部服务及CRO费用下降64.7%至21.45万美元[85][86] - 员工薪酬支出增长10.2%至11.29万美元[85] - 股份支付费用增长21.5%至2.34万美元[85] - 其他研发费用下降4.9%至4.81万美元[85] 管理费用变化 - 行政费用同比下降8.7%至86.32万美元，主要因知识产权相关成本减少[83][87] - 管理费用微增1.1%至279.7万美元，法律费用增加被咨询费下降抵消[90][93] 利息收入表现 - 利息收入增长62.2%至4.55万美元，主要因投资利率上升[83][89] - 利息收入增长23%至8.7万美元，主要因投资利率上升[90][95] 其他费用变化 - 其他费用增长44.8%至2.6万美元，主因汇率波动影响[90][94] 盈利与亏损状况 - 营业亏损同比改善38.4%至84.78万美元[83] - 净亏损同比收窄40.5%至80.4万美元[83] - 运营亏损扩大33.1%至515.5万美元，净亏损增长33.3%至507万美元[90] 现金流与资本状况 - 现金及等价物降至1380万美元（2021年末1820万美元），营运资本减少420万美元至1310万美元[96] - 经营活动现金流流出390万美元，投资活动现金流因支付50万美元平台授权费而流出50万美元[98][99] - 累计赤字达1.876亿美元，公司存在持续经营重大疑虑但预计资金可维持至2024年第一季度[96][97] 合规与风险因素 - 纳斯达克最低股价合规期至2022年11月30日，可能面临退市风险[97]

特许权使用费收入表现 - 特许权使用费收入为41.67万美元，同比增长44.9%[78][79] - 特许权使用费收入增长68.3%至80.57万美元，较去年同期的47.88万美元增加32.69万美元[85][86] 研发费用变化 - 研发费用为207.75万美元，同比增长296.1%[78][80] - 其中130.5万美元为DNase肿瘤平台许可相关的IPR&D费用[80] - 剔除IPR&D后研发费用为77.25万美元，同比增长47.3%[80] - 研发费用激增175.4%至317.89万美元，主要由于130.5万美元的IPR&D费用支出[85][87] 外部服务及CRO费用投入 - 外部服务及CRO费用为59.84万美元，主要因XCART平台投入增加[80][81] - 外部服务和CRO费用增长75.8%至142.67万美元，主要投入XCART平台开发[87] 行政管理费用变化 - 行政管理费用为102.63万美元，同比增长15.2%[78][82] 运营亏损状况 - 运营亏损为268.71万美元，同比增长138.3%[78] - 总运营成本增长71.8%至511.25万美元，运营亏损扩大72.5%至430.68万美元[85] 净亏损状况 - 净亏损为267.22万美元，同比增长141.5%[78] - 净亏损扩大73.9%至426.58万美元，较去年同期增加181.32万美元[85] 利息收入变化 - 利息收入为1.6万美元，同比下降23.0%[78][84] 其他费用及影响因素 - 其他费用为0.11万美元，主要受汇率变动影响[78][83] 现金流及资金状况 - 现金及现金等价物从1820万美元下降至1490万美元，营运资金减少320万美元至1410万美元[92] - 经营活动现金流流出280万美元，投资活动现金流流出50万美元用于DNase肿瘤平台授权[94][95] - 公司现有资金预计可维持运营至2023年第三季度[93] 累计赤字情况 - 累计赤字达1.868亿美元，较2021年末增加430万美元[92] 监管合规事项 - 纳斯达克收到最低股价违规通知，需在2022年11月30日前恢复合规[93]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 45-2952962 (IRS Employer Identification No.) 40 Speen Street, Sui ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nev ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 4 ...

NASDAQ: XBIO xeneticbio.com Expanding the Potential of CAR T Cell Therapy Investor Presentation M a y 2021 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 45-2952962 (IRS Employer Identification No.) 40 Speen Street, Suite 102 Framingham, Massachusetts 01701 (Address of principal executive offices and zip code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 781-778-7720 For the transition period from to Commission File Number: 001- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of i ...

NASDAQ: XBIO xeneticbio.com Expanding the Potential of CAR T Cell Therapy Investor Presentation M a r c h 2021 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by w ...